Ginkgo Bioworks Inc. (DNA)
| Bid | 7.35 |
| Market Cap | 426.84M |
| Revenue (ttm) | 227.04M |
| Net Income (ttm) | -547.03M |
| EPS (ttm) | -10.54 |
| PE Ratio (ttm) | -0.7 |
| Forward PE | -2.1 |
| Analyst | Sell |
| Ask | 7.37 |
| Volume | 265,153 |
| Avg. Volume (20D) | 1,713,219 |
| Open | 7.47 |
| Previous Close | 7.34 |
| Day's Range | 7.18 - 7.63 |
| 52-Week Range | 5.00 - 45.20 |
| Beta | 1.35 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Bi...
Analyst Forecast
According to 5 analyst ratings, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $10, which is an increase of 35.96% from the latest price.
Stock Forecasts
1 week ago · accessnewswire.com
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price RequirementSTONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a...
